Consolidated Financial Statements

and

Supplementary Information

CONTENTS

Accountants' Review Report	1
Financial Statements	
Consolidated Statement of Financial Position	2
Consolidated Statement of Activities and Changes in Net Assets	3
Consolidated Statement of Cash Flows	4
Notes to Consolidated Financial Statements	5-8
Supplementary Information	
Schedule of Departmental Assets, Liabilities, and Net Assets	9
Schedule of Departmental Revenues and Expenses	10

STARKWEATHER & FESTER P.C. CERTIFIED PUBLIC ACCOUNTANTS

4000 NORTH CENTRAL AVENUE SUITE 1000 PHOENIX, ARIZONA 85012-1907

(602) 264-3077 FAX (602) 265-624:

Accountants' Review Report

To the Board of Directors Alcor Life Extension Foundation, Inc. Scottsdale, Arizona

We have reviewed the accompanying consolidated statement of financial position of Alcor Life Extension Foundation, Inc. and Subsidiaries as of December 31, 1999, and the related consolidated statements of activities and changes in net assets and cash flows for the year then ended, in accordance with Statements on Standards for Accounting and Review Services issued by the American Institute of Certified Public Accountants. All information included in the consolidated financial statements is the representation of the management of Alcor Life Extension Foundation, Inc. and Subsidiaries.

A review consists principally of inquiries of Company personnel and analytical procedures applied to financial data. It is substantially less in scope than an audit in accordance with generally accepted auditing standards, the objective of which is the expression of an opinion regarding the financial statements taken as a whole. Accordingly, we do not express such an opinion.

Based on our review, we are not aware of any material modifications that should be made to the accompanying financial statements in order for them to be in conformity with generally accepted accounting principles.

Our review was made for the purpose of expressing limited assurance that there are no material modifications that should be made to the financial statements in order for them to be in conformity with generally accepted accounting principles. The information included in the accompanying schedule of departmental assets, liabilities and net assets and the schedule of departmental revenues and expenses is presented only for supplementary analysis purposes. Such information has been subjected to the inquiry and analytical procedures applied in the review of the basic financial statements, and we are not aware of any material modifications that should be made thereto.

February 8, 2000

Starbweather & Fester P. C.

CONSOLIDATED STATEMENT OF FINANCIAL POSITION (See Accountants' Review Report)

December 31, 1999

ASSETS

Current assets	
Cash and cash equivalents	\$ 132,039
Investments	1,125,215
Accounts receivable	104,064
Deposits	30,267
Total current assets	1,391,585
Property and equipment	
Land	150,000
Building and improvements	708,067
Equipment	457,111
	1,315,178
Less accumulated depreciation	322,997
	992,181
Prepaid suspensions and standby	526,345
Investment in building	32,000
License, net of accumulated amortization of \$16,667	8.333
Total assets	\$ 2,950,444
LIABILITIES AND NET ASSETS	
Current liabilities	
Current portion of long-term debt	\$ 4,302
Security deposits	9,289
Capital lease obligations	8,937
Deferred suspension revenue	533,887
Deferred patient care reserve	1,431,797
Total liabilities	1,988,212
Unrestricted net assets	
Controlling interests	816,272
Minority interests	145,960
Total net assets	962,232
Total liabilities and net assets	\$ 2,950,444

CONSOLIDATED STATEMENT OF ACTIVITIES AND CHANGES IN NET ASSETS (See Accountants' Review Report)

	Unrestricted	Temporarily Restricted	T-4-1
Revenue and support:	Omesuicted	Restricted	Total
Membership dues	\$ 185,129		\$ 185,129
Rental income	113,700		113,700
Contributions	105,940		105,940
Suspension and standby	67,100		67,100
Interest	31,951		31,951
Gain on investments	155,774		155,774
BioTransport, Inc. expense reimbursement	32,481		32,481
Other	44,767		44,767
Net assets released from restrictions	, , , , , , , , , , , , , , , , , , , ,		, ,
Satisfaction of donor requirements	6,152	\$ (6,152)	
Total revenues	742,994	(6,152)	736,842
Expenses:			
Salaries and related	170,127		170,127
Advertising	2,715		2,715
Depreciation and amortization	45,111		45,111
Magazine and publications	40,672		40,672
Emergency response	15,549		15,549
Insurance	14,787		14,787
Legal and professional	34,301		34,301
Medical supplies	34,220		34,220
Office expense	12,081		12,081
Other	24,480		24,480
Postage	14,582		14,582
Repairs and maintenance	29,441		29,441
Suspension and standby	26,911		26,911
Telephone	18,607		18,607
Travel	2,968		2,968
Taxes and licenses	30,503		30,503
Utilities	16,985		<u> </u>
Total expenses	534,040		534,040
Increase in net assets before minority interest	208,954	(6,152)	202,802
Minority interest in income	(5,575)		(5.575)
Increase in net assets	203,379	(6,152)	197,227
Net assets, beginning of year	612,893	6,152	619,045
Net assets, end of year	\$ 816,272		<u>\$ 816.272</u>

CONSOLIDATED STATEMENT OF CASH FLOWS (See Accountants' Review Report)

Cash flows from operating activities Increase in net assets Adjustment to reconcile change in net assets to net cash provided by operating activities	\$ 197,227
Minority interest in share of net income Depreciation and amortization Gain on investments Increase in accounts receivable	5,575 45,111 (155,774) (33,316)
Increase in deposits Decrease in security deposits	(7,050) (4,363)
Net cash provided by operating activities	47,410
Cash flows from investing activities	
Purchase of investments Increase in prepaid suspensions and standby Purchase of equipment and leasehold improvements	(3,701) (186,328) (83,697)
Net cash used in investing activities	(273,726)
Cash flows from financing activities Proceeds from deferred suspension revenue Proceeds from deferred patient care reserve Payments on capital leases	186,328 70,000 (3,763)
Net cash provided by financing activities	252,565
Net increase in cash and cash equivalents	26,249
Cash and cash equivalents, beginning of year	105,790
Cash and cash equivalents, end of year	\$ 132,039
Cash paid for interest during period	\$ 1,634
Non-cash investing and financing activities: Equipment acquired under capital lease	\$ 5,068

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 1999

NOTE 1 - BACKGROUND AND SUMMARY OF ACCOUNTING POLICIES

Alcor Life Extension Foundation, Inc. (Alcor) is a California non-profit organization formed under Section 501(c)(3) of the Internal Revenue Code. Alcor conducts its primary operations in Scottsdale, Arizona. Alcor is funded primarily through contributions and membership dues from its members, and rental income.

Alcor's primary exempt purpose is research and education in the science of cryonic storage and cryonic suspension.

The significant accounting policies of Alcor follow:

<u>Principles of Consolidation</u>: The consolidated financial statements for the year ended December 31, 1999 include all accounts of Alcor Life Extension Foundation, Inc. and its subsidiaries, the wholly owned Alcor Patient Care Trust and the 57.57% owned Cryonics Properties, LLC. All significant intercompany transactions have been eliminated.

<u>Basis of Presentation</u>: Financial statement presentation follows the recommendations of the Financial Accounting Standards Board in its Statement of Financial Accounting Standards (SFAS) No. 117, Financial Statements of Not-for-Profit Organizations. Under SFAS No. 117, Alcor is required to report information regarding its consolidated financial position and activities according to three classes of net assets: unrestricted net assets, temporarily restricted net assets, and permanently restricted net assets. Alcor has no temporarily or permanently restricted net assets at December 31, 1999.

<u>Use of Estimates</u>: In preparing financial statements in conformity with generally accepted accounting principles, management is required to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates.

<u>Cash and cash equivalents</u>: For purposes of the statement of cash flows, Alcor considers all highly liquid investments purchased with an original maturity of three months or less to be cash equivalents.

<u>Investments</u>: Investments are recorded at market. Unrealized gains and losses are accounted for as investment income.

NOTES TO CONSOLIDATE FINANCIAL STATEMENTS

December 31, 1999

NOTE 1 - BACKGROUND AND SUMMARY OF ACCOUNTING POLICIES - CONTINUED

<u>Property and equipment</u>: Property and equipment costing \$500 or more are recorded at cost, or at estimated fair value at the date of gift if donated.

Depreciation and amortization are computed using the straight-line method based on estimated economic lives of the assets as follows:

Building and improvements 39-40 years
Equipment 5-20 years
Automobile 5 years

Investment in building: Interests in buildings held for investment are recorded at cost.

<u>Prepaid suspensions and standby/Deferred suspension revenue</u>: Prepaid suspensions and standby services are recorded as deferred revenue. Alcor recognizes suspension and standby revenue as the services are performed.

<u>Deferred patient care reserve</u>: Upon suspension of a patient, a specified amount of the suspension revenue is deferred and invested into the Alcor Patient Care Trust to be used for patient re-animation, at which time Alcor would recognize the revenue.

<u>Income taxes</u>: Alcor is exempt from Federal income taxes as an organization other than a private foundation under Section 501(c)(3) of the Internal Revenue Code.

Restricted and Unrestricted Revenue: Contributions that are restricted by the donor are reported as increases in unrestricted net assets if the restrictions expire (that is, when a stipulated time restriction ends or purpose restriction is accomplished) in the reporting period in which the revenue is recognized. All other donor-restricted contributions are reported as increases in temporarily or permanently restricted net assets, depending on the nature of the restrictions. When a restriction expires, temporarily restricted net assets are reclassified to unrestricted net assets and reported in the Statement of Activities as net assets released form restrictions.

NOTE 2 - CONCENTRATION OF CREDIT RISK

Alcor maintains cash balances and cash equivalents at financial institutions. At December 31, 1999, Alcor had no deposits at financial institutions in excess of federal insurance limits. Alcor has not experienced any losses in such accounts and believes it is not exposed to any significant risk on cash and cash equivalents.

NOTE 3 - INVESTMENTS

Investments consist of shares in mutual funds, and are stated at market value at December 31, 1999. Interest and investment income for the year ended December 31, 1999 were \$31,951 and \$155,774, respectively.

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 1999

NOTE 4 - PREPAID SUSPENSIONS AND STANDBY

Alcor must maintain prepaid suspensions and standby services in separate accounts for each member, per the suspension contracts. Alcor's bylaws require that the accounts be invested conservatively in depositories insured against loss by an agency of the Federal Government. At December 31, 1999, Alcor had invested the monies received for prepaid suspensions and standby services in certificates of deposit at financial institutions insured by the Federal Deposit Insurance Corporation up to \$100,000 per account. The following is a summary of those investments.

		Amount insured
	Total invested	by FDIC
Certificates of deposit	\$ 261,000	\$ 261,000
Insured deposit accounts	265,345	265,345
Total	\$ 526,345	\$ 526,345

NOTE 5 - LICENSE

Alcor purchased a license from Cryopreservation Technologies to use a new perfusate solution for laboratory research. The cost of the license was \$25,000 and is being amortized over 5 years. Amortization expense is included with depreciation and amortization expense.

NOTE 6 - CAPITAL LEASES

The cost of equipment acquired under capital leases was \$20,942 as of December 31, 1999. Amortization of assets held under capital leases is included with depreciation and amortization expense. Accumulated amortization was \$16,327 at December 31, 1999.

The following is a schedule of future minimum lease payments under capital leases, with the present value of net minimum lease payments as of December 31, 1999.

Year ending December 31,	
2000	\$ 5,625
2001	5,548
2002	3,038
2003	1,366
2004	227
	15,804
Less amount representing interest Present value of future minimum	<u>2.565</u>
lease payments	<u>\$ 13,239</u>

NOTES TO CONSOLIDATED FINANCIAL STATEMENTS

December 31, 1999

NOTE 7 - DEFERRED PATIENT CARE RESERVE

Alcor has a financial obligation to fund the maintenance and re-animation of members who have undergone cryonic suspension. The actual amount of future expenses required to meet this obligation is unknown due to the uncertainty of how long Alcor must maintain its members in cryonic suspension and the uncertain costs of re-animation, if re-animation becomes scientifically and legally possible in the future.

NOTE 8 - FUNCTIONAL EXPENSES

Alcor conducts research and education in the field of cryonic suspension and storage. Expenses related to providing these services for the year ended December 31, 1999, are as follows:

Research and education	\$248,452
General and administrative	285,588
	\$534,040

NOTE 9 – RELATED PARTY TRANSACTIONS

Several members of Alcor's board of directors and management own shares in BioTransport, Inc. BioTransport, Inc. uses Alcor's personnel, facilities, equipment and supplies in its operations. BioTransport, Inc. reimburses Alcor for Alcor's actual cost in this regard. Alcor also receives overhead fees calculated at 50 percent of actual costs of services and materials utilized by BioTransport, Inc. BioTransport, Inc.'s reimbursements to Alcor for the year ended December 31, 1999, were \$32,481.

SCHEDULE OF DEPARTMENTAL ASSETS, LIABILITIES AND NET ASSETS (See Accountants' Review Report)

December 31, 1999

-	General	Clinical Research	Laboratory Research	Endowment	Patient Care Trust	Cryonics Property, LLC	Eliminating	Total
ASSETS					-			
Cash and cash equivalents	\$ 37,982	\$ 1,310	\$ 6,340	\$ 38,097		\$ 48,310		\$ 132,039
Investments				58,353	\$ 1,066,862			1,125,215
Accounts receivable	104,024	40						104,064
Deposits						30,267		30,267
Due to/from other depts.	(22,659)	(273,761)	(24,601)	325,236	(4,215)			
Total current assets	119,347	(272,411)	(18,261)	421,686	1,062,647	78,577		1,391,585
Property and equipment Land						150,000		150,000
Building and improvement	2,594				5,421	700,052		708,067
Equipment	78.741	40,182	30,742		307,446			457,111
Less accum. depreciation	81,335 65,222	40,182 13.622	30,742 11,957		312,867 124,597	850,052 107,599		1,315,178 322.997
	16,113	26,560	18,785		188,270	742,453		992,181
					•	•		ŕ
Mortgage note					466,807	(466,807)		
Prepaid suspensions and								
standby		526,345						526,345
Investment in building					230,974		\$(198,974)	32,000
License, net of accumulated amortization of \$13,667			8.333					8,333
Total assets	\$ 135,460	\$ 280,494	\$ 8,857	\$ 421,686	\$ 1,948,698	\$ 354,223	<u>\$(198,974)</u>	#VALUE!
LIABILITIES AND NET Current liabilities Current portion of long-term debt	ASSETS \$ 3,453	\$ 849						\$ 4,302
long-term deat	3 J, 4 JJ	3 049						3 4,302
Security deposits Capital lease obligations Deferred suspension revenue Deferred patient care reserve	5,401	3,536 533,887			\$ 1,431,797	\$ 9,289		9,289 8,937 533,887 1,431,797
Total liabilities	8,854	538,272			1,431,797	9,289		1,988,212
Net assets	-,	,			2,102,112	7,2-17		-,,
Unrestricted								
Controlling interests Minority interests	126,606	(257,778)	\$ 8,857	\$ 421,686	516,901	344,934	(344,934) 145,960	816,272 145,960
Total net assets	126,606	(257,778)	8,857	421,686	516,901	344,934	(198,974)	962,232
Total liabilities and net assets	\$ 135,460	\$ 280,494	\$ 8,857	\$ 421,686	\$ 1.948,698	\$ 354,223	\$ (198,974)	\$2,950,444

SCHEDULE OF DEPARTMENTAL REVENUES AND EXPENSES (See Accountants' Review Report)

	General	Clinical Research	Laboratory Research	Endowment	Patient Care Trust	Cryonics Property, LLC	Eliminating	Total
Revenue and support:								
Membership dues Rental income	\$185,129					\$ 137,877	\$ (24,177)	\$ 185,129 113,700
Contributions	102,340	\$ 800		\$ 2,800		\$157,677	w (24,177)	105,940
Suspensions and standby	102,5 10	67,100		2,000				67,100
Interest	1.139	07,100	\$ 228	3,107	\$ 74,797		(47,320)	31,951
Gain on investments	1,137	1,828	J 220	1,164	160,368		(7,586)	155,774
BioTransport, Inc. expense		1,020		1,104	100,508		(7,580)	133,774
reimbursement	32,481							22.401
Other	41.565					3.202		32,481 44,767
								44,707
Total revenues	362,654	69,728	228	7,071	235,165	141,079	(79,083)	736,842
Expenses:								
Salaries and related	75,683	48,077	24,571		21,796			170,127
Allocation	20,979	•	(20,979)		,			,
Advertising	2,580		, , ,			135		2,715
Depreciation and								,
amortization	4,871	3,272	5,000		14,346	17,622		45,111
Magazine and publications	40,423	249				,		40,672
Emergency response	300	15,249						15,549
Insurance	7,109	3,781	1,906		1,207	784		14,787
Interest	·	ŕ	,		,	47,320	(47,320)	- ,
Legal and professional	16,753	3,125			3,914	10,509	• • • •	34,301
Medical supplies		13,281			20,939	,		34,220
Office expense	11,989	88			4			12,081
Other	17,733	3,593	16		2,054	1,084		24,480
Postage	11,022	959	350		2,251	•		14,582
Rent	11,841	4,886	5,321		2,129		(24,177)	,
Repairs and maintenance	12,817	938				15,686	, , ,	29,441
Suspension and standby		26,911				•		26,911
Telephone	17,538	1,069						18,607
Travel	1,243	722			1,003			2,968
Taxes and licenses	199	14			-	30,290		30,503
Utilities	7,045	2.464	2.243		745	4,488		16,985
T . 1	260 126	100 (50			# 0.000		451 405X	62.4.0.40
Total expenses	260,125	128,678	18.428		70,388	127,918	<u>(71,497</u>)	534,040
Increase (decrease) in net assets								
before minority interest	102,529	(58,950)	(18,200)	7,071	164,777	13,161	(7,586)	202,802
, -	,,-	(20,200)	(.0,200)	,,,,,	20.,	,	(-,- 30)	,
Minority interest in income							(5,575)	(5,575)
Net assets, beginning of year	24,077	(198,828)	27.057	414,615	352,124	331,773	(331.773)	619.045
Net assets, end of year	\$126,606	<u>\$(257,778)</u>	\$ 8,857	\$421,686	\$516,901	<u>\$344,934</u>	<u>\$(344,934)</u>	\$816,272